The Use of Low Intensity Shock Wave Therapy for the Treatment of Provoked Vestibulodynia Disorder (PVD)

Sponsor
Rambam Health Care Campus (Other)
Overall Status
Completed
CT.gov ID
NCT04545255
Collaborator
(none)
32
1
2
19
1.7

Study Details

Study Description

Brief Summary

Provoked vestibulodynia (PVD) is an exhausting pain syndrome that immensely affects quality of sexual life, and consequently negatively affects quality of life. Low intensity shock wave therapy produces physical forces that lead to pain relief.

Aim: To evaluate the feasibility, safety and efficacy of low-intensity shockwave therapy in patients with provoked vestibulodynia.

Methods: A double-blinded, randomized, sham-controlled, prospective study of 32 women. The treatment protocol included a series of treatments, performed twice a week for 6 weeks. Each treatment consisted of 500 pulses of low intensity shockwaves (0.09 mJ/〖mm〗^2 ) using the "Medispec ED-1000®" shock wave generator or sham.

Condition or Disease Intervention/Treatment Phase
  • Device: Shockwave treatment
N/A

Detailed Description

The study was a single center, double-blinded, randomized, sham-controlled, prospective study. Study eligibility criteria were treatment at the Neuro-urology Unit in Rambam Medical Center, during January 2018 - January 2020 and a diagnosis of PVD. PVD diagnosis was based on description of the pain and on a positive cotton swab test15.

Women were randomized at a 2:1 ratio to treatment or sham groups. The treatment protocol included a series of treatments, performed twice a week for 6 weeks, for a total of 12 sessions. Each treatment consisted of 500 pulses of low intensity shockwaves (0.09 millijoul/〖mm〗^2 ) using the "Medispec ED-1000®" shock wave generator. The sham protocol included the same treatment protocol without shock wave generator activation. The patients were evaluated three times throughout the trial by an investigator blinded to the group allocation: before the first treatment, and one and three months after the twelfth treatment. Pain was assessed by both subjective and objective measures. The primary outcome measure was a change in dyspareunia, as assessed by scores on the 10-point visual analogue scale (VAS) (range 0-10 ).

Secondary outcome measures for evaluating pain were increases in pain threshold and tolerance, assessed by a quantitative validated algometer test16, 17, the Wong-Baker pain FACES scale (range 0-10)18, the Female Sexual Function Index (FSFI) (range 2-38)19 and the Patients' Global Impression of Change scale (PGIC) (first component range 0-7; 0=no change, 7=a great deal better; second component range 0-10; 0=much better and 10=much worse)20. The PGIC assessed the self-reported impression of a general change due to the intervention.

The algometer applied was a very basic and simple device that was assembled and used at our unit after validating its safety, accuracy, and adequacy in evaluating introitus pain vs control (doctorate dissertation). For assessing the pain threshold with the algometer, radial pressure (mmHg) was applied by progressively inflating a cylindrical balloon inserted in the introitus. The participant was required to report the first painful sensation, and this pressure, defined as the threshold pressure, was registered. The measurement was performed sequentially 4 times and the average of the measured pressures was considered the first pain threshold). Finally, for pain tolerance measurement, the participant was again asked to report when she had reached her pain limit (1-10 on the verbal scale ) upon continuous pressure

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A double-blinded, randomized, sham-controlled, prospective studyA double-blinded, randomized, sham-controlled, prospective study
Masking:
Double (Participant, Investigator)
Masking Description:
Shockwave probes were either active or sham (by blocking energy transfer from probe)
Primary Purpose:
Treatment
Official Title:
The Use of Low Intensity Shock Wave Therapy for the Treatment of Provoked Vestibulodynia Disorder (PVD)
Actual Study Start Date :
Jun 21, 2018
Actual Primary Completion Date :
Oct 30, 2019
Actual Study Completion Date :
Jan 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: active

A shockwave device with a probe that conveys shockwave energy

Device: Shockwave treatment
ED 1000 shockwave generator

Sham Comparator: sham

A shockwave device with specially designed probe which has the shockwave energy blocked

Device: Shockwave treatment
ED 1000 shockwave generator

Outcome Measures

Primary Outcome Measures

  1. Visual Analog Scale (VAS) [1 year]

    The primary outcome was a change in dyspareunia, as assessed by scores on the 10-point Visual Analogue Scale where 1 is the minimum score meaning painless and 10 is the maximum score meaning excruciating pain

Secondary Outcome Measures

  1. Algometer testing [1 year]

    measures threshold of pain in mmHg, where any threshold below 100 mmHg is considered pathological

  2. Wong-Baker pain FACES scale [1 year]

    from a scale of 1 to five showing sad face for score 1 and very happy face for score 5

  3. Female Sexual Function Index (FSFI) [1 year]

    A validated questionnaire assessing female sexual dysfunction, any score above 22.5 is pathological

  4. Patients' Global Impression of Change scale. [1 year]

    one question with a scale from -3 to+3 where 0 is not better nor worse, -3 is much worse and +3 is much better

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Above age 18 years

  • Diagnosis of provoked vestibulodynia by a gynecologist at least 3 month prior to study date

  • Positive cotton swab test

  • Pain during intercourse/ tampon insertion, gynecologic examination

  • Cognitively and physically adapted for undergoing treatment

Exclusion Criteria:
  • Pregnancy or lactating

  • History of pelvic or external genitalia irradiation during the past year

  • Any chronic neurological disorder causing local pain

  • Any pelvic inflammatory process

  • Any psychiatric disorders

  • Investigators impression of patient being eligible for the study (non compliance etc..)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rambam Healthcare Campus Haifa Northern Region Israel 31096

Sponsors and Collaborators

  • Rambam Health Care Campus

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
i_gruenwald, Professor, Director of the Neuro- urology unit, Rambam healthcare campus, Rambam Health Care Campus
ClinicalTrials.gov Identifier:
NCT04545255
Other Study ID Numbers:
  • 0098-18-rmc
First Posted:
Sep 10, 2020
Last Update Posted:
Sep 10, 2020
Last Verified:
Sep 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 10, 2020